Mevinolin, An Inhibitor Of Cholesterol Synthesis, Induces MRNA For Low Density Lipoprotein Receptor In Livers Of Hamsters And Rabbits

This groundbreaking 1986 study helped explain how statin medications work to lower cholesterol levels in the body. Researchers gave mevinolin (now known as lovastatin, one of the first statin drugs) to hamsters and rabbits, then measured changes in their liver cells and blood cholesterol levels.

The scientists discovered that mevinolin doesn't just block cholesterol production - it also triggers the liver to make more LDL receptors. These receptors act like tiny vacuum cleaners on liver cells, pulling harmful LDL cholesterol out of the bloodstream. In the study, animals receiving mevinolin showed a 2.5 to 3-fold increase in these beneficial receptors, along with dramatic reductions in blood cholesterol (80-90% in some cases).

Importantly, the researchers tested this mechanism in rabbits with a genetic condition similar to familial hypercholesterolemia in humans - a disorder where people have defective cholesterol receptors. Even in these animals, mevinolin increased receptor production, though the cholesterol-lowering effect was limited because their receptors don't function properly.

This research was crucial for understanding why statins became such powerful tools for preventing heart disease. By identifying this dual mechanism - blocking cholesterol production while boosting the body's natural cholesterol removal system - scientists laid the groundwork for developing more effective cardiovascular treatments. Today, statins remain one of the most prescribed medications for managing cholesterol and reducing heart disease risk in clinical practice.